A PARP Inhibitor for Ovarian Cancer | NEJM
Quick Take Video Summary from The New England Journal of Medicine — A PARP Inhibitor for Ovarian Cancer
Related Articles
Exclusion of Elective Care from Hospital Financial Assistance Policies — Arresting a Troubling Development | NEJM
The financial assistance policies of some U.S. hospitals now define medical necessity much more restrictively than it has conventionally been understood, as covering only services…
Incarcerated Femoral Hernia | NEJM
A 77-year-old woman presented with a 2-day history of abdominal pain, nausea, and vomiting. CT of the abdomen revealed herniation of a loop of ileum…
Chronic Obstructive Pseudoemphysema | NEJM
TEN years have elapsed since Swyer and James1 and Macleod2 described an unusual form of hyperlucency of one lung that appeared to be due to…
Who Will Care for America? Immigration Policy and the Coming Health Workforce Crisis | NEJM
In the current anti-immigrant political environment in the United States, what will happen when immigrants who work in the health care system are forced to…
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer | NEJM
In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo plus…
Whipple’s Disease with Endocarditis | NEJM
A 51-year-old man presented with a 3-month history of weight loss, diarrhea, and fever. Transthoracic echocardiography showed vegetations on the aortic and mitral valves. A…
The Faulty Logic behind the Supreme Court’s Failure to Protect Trans Minors | NEJM
The U.S. Supreme Court recently upheld Tennessee’s ban on gender-affirming hormonal treatment for transgender minors. This decision will have profound implications.
Intravenous Tenecteplase before Thrombectomy in Stroke | NEJM
The safety and efficacy of treatment with intravenous tenecteplase before endovascular thrombectomy in patients with acute ischemic stroke due to large-vessel occlusion remain uncertain. In…
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer | NEJM
In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo plus…
Libraries Burned, a Life Lived | NEJM
As her patients near the end of life, an infectious disease physician who knows their stories sometimes needs to step out of her proverbial lane…